Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

P2Y4 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Agonist-induced Serine344/Serine345 phosphorylation of the P2Y Receptor
pS344/pS345-P2Y4 (phospho-P2Y Purinoceptor 4...
Serine344/Serine345 (S344/S345) is a major phosphorylation site of the P2Y4 receptor. The pS344/pS345-P2Y4 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. S344/S345...
$ 375.00 *
Details
NEW
Agonist-induced Serine339 phosphorylation of the P2Y Receptor 4
pS339-P2Y4 (phospho-P2Y Purinoceptor 4 Antibody)
Serine339 (S339) is a major phosphorylation site of the P2Y4 receptor. The pS339-P2Y4 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. S339 phosphorylation is a key regulator of...
$ 375.00 *
Details
NEW
Agonist-induced Threonine351 phosphorylation of the P2Y Receptor 4
pT351-P2Y4 (phospho-P2Y Purinoceptor 4 Antibody)
Threonine351 (T351) is a major phosphorylation site of the P2Y4 receptor. The pT351-P2Y4 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. T351 phosphorylation is a key regulator of...
$ 375.00 *
Details

P2Y14

The human P2Y4 receptor is activated by uridine nucleotidic triphosphates (not diphosphates) and is considered to be a pyrimidinoceptor. ATP is a partial agonist at the human P2Y4 receptor. P2Y4 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine339 (pS339-P2Y4), serine344/serine345 (pS344/pS345-P2Y4) and threonine351 (pT351-P2Y4). S339, S344/pS345 and T351 can also be phosphorylated by PKC. This nomenclature refers to the human P2Y4. For more information on P2Y4 pharmacology please refer to the IUPHAR database. For further reading refer to:

Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev. 2006 Sep;58(3):281-341. doi: 10.1124/pr.58.3.3. PMID: 16968944; PMCID: PMC3471216.

Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kügelgen I, Li B, Miras-Portugal MT, Novak I, Schöneberg T, Perez-Sen R, Thor D, Wu B, Yang Z, Müller CE. Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol. 2020 Jun;177(11):2413-2433. doi: 10.1111/bph.15005. Epub 2020 Apr 6. PMID: 32037507; PMCID: PMC7205808.

Jacobson KA, Paoletta S, Katritch V, Wu B, Gao ZG, Zhao Q, Stevens RC, Kiselev E. Nucleotides Acting at P2Y Receptors: Connecting Structure and Function. Mol Pharmacol. 2015 Aug;88(2):220-30. doi: 10.1124/mol.114.095711. Epub 2015 Apr 2. PMID: 25837834; PMCID: PMC4518082.

The human P2Y4 receptor is activated by uridine nucleotidic triphosphates (not diphosphates) and is considered to be a pyrimidinoceptor. ATP is a partial agonist at the human P2Y4 receptor.... read more »
Close window
P2Y4 Receptor Antibodies

P2Y14

The human P2Y4 receptor is activated by uridine nucleotidic triphosphates (not diphosphates) and is considered to be a pyrimidinoceptor. ATP is a partial agonist at the human P2Y4 receptor. P2Y4 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine339 (pS339-P2Y4), serine344/serine345 (pS344/pS345-P2Y4) and threonine351 (pT351-P2Y4). S339, S344/pS345 and T351 can also be phosphorylated by PKC. This nomenclature refers to the human P2Y4. For more information on P2Y4 pharmacology please refer to the IUPHAR database. For further reading refer to:

Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev. 2006 Sep;58(3):281-341. doi: 10.1124/pr.58.3.3. PMID: 16968944; PMCID: PMC3471216.

Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kügelgen I, Li B, Miras-Portugal MT, Novak I, Schöneberg T, Perez-Sen R, Thor D, Wu B, Yang Z, Müller CE. Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol. 2020 Jun;177(11):2413-2433. doi: 10.1111/bph.15005. Epub 2020 Apr 6. PMID: 32037507; PMCID: PMC7205808.

Jacobson KA, Paoletta S, Katritch V, Wu B, Gao ZG, Zhao Q, Stevens RC, Kiselev E. Nucleotides Acting at P2Y Receptors: Connecting Structure and Function. Mol Pharmacol. 2015 Aug;88(2):220-30. doi: 10.1124/mol.114.095711. Epub 2015 Apr 2. PMID: 25837834; PMCID: PMC4518082.

Recently viewed